This inventor holds 1 USPTO granted patent. Top assignees: Massachusetts Institute of Technology, The General Hospital Corporation. Active years: 2016.
Company Filing History:
1 out of 8,578 
1 out of 3,071 
Years Active: 2016
Title: The Innovative Contributions of Josh Ketterman
Introduction
Josh Ketterman is an accomplished inventor based in Cambridge, MA (US). He has made significant strides in the field of neuroscience, particularly in the treatment of bipolar disorder and other brain disorders. His work focuses on the use of chemical compounds to modulate GSK-3 signaling, which is crucial for developing effective therapies for neurological and psychiatric conditions.
Latest Patents
Ketterman holds a patent for the "Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders." This invention involves the use of chemical compounds that can inhibit GSK-3 and stabilize β-catenin. The patent outlines various compositions comprising these compounds and provides methods for their application in treating subjects with neurological diseases and psychiatric disorders. Notably, the invention includes the use of compounds such as ruboxistaurin, enzastaurin, sunitinib, midostaurin, lestaurtinib, 7-hydroxystaurosporine, and Chir99021, often administered in combination with Lithium.
Career Highlights
Throughout his career, Ketterman has worked with prestigious institutions, including the Massachusetts Institute of Technology and The General Hospital Corporation. His experience in these organizations has contributed to his expertise in the field of neuroscience and the development of innovative treatments.
Collaborations
Ketterman has collaborated with notable colleagues, including Stephen J. Haggarty and Daniel Fass. These partnerships have further enhanced his research and development efforts in the realm of neurological and psychiatric disorders.
Conclusion
Josh Ketterman's contributions to the field of neuroscience through his innovative patent and collaborations with esteemed colleagues highlight his commitment to advancing treatments for brain disorders. His work continues to pave the way for new therapeutic approaches that can significantly impact the lives of those affected by these conditions.